Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Long-Term Deferred Tax (2016 - 2023)

Historic Long-Term Deferred Tax for BeOne Medicines (BEIGF) over the last 8 years, with Q4 2023 value amounting to $2.0 billion.

  • BeOne Medicines' Long-Term Deferred Tax fell 238.3% to $2.0 billion in Q4 2023 from the same period last year, while for Dec 2023 it was $2.0 billion, marking a year-over-year decrease of 238.3%. This contributed to the annual value of $2.0 billion for FY2023, which is 238.3% down from last year.
  • BeOne Medicines' Long-Term Deferred Tax amounted to $2.0 billion in Q4 2023, which was down 238.3% from $2.1 billion recorded in Q4 2022.
  • BeOne Medicines' Long-Term Deferred Tax's 5-year high stood at $2.1 billion during Q4 2022, with a 5-year trough of $30.5 million in Q1 2019.
  • For the 5-year period, BeOne Medicines' Long-Term Deferred Tax averaged around $328.5 million, with its median value being $66.0 million (2020).
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first surged by 15583.34% in 2019, then crashed by 238.3% in 2023.
  • BeOne Medicines' Long-Term Deferred Tax (Quarter) stood at $37.9 million in 2019, then surged by 74.07% to $66.0 million in 2020, then surged by 61.98% to $106.8 million in 2021, then soared by 1846.59% to $2.1 billion in 2022, then dropped by 2.38% to $2.0 billion in 2023.
  • Its Long-Term Deferred Tax was $2.0 billion in Q4 2023, compared to $2.1 billion in Q4 2022 and $103.4 million in Q2 2022.